๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Guanzhou
Clinical trial register · China

Clinical Trials in Guanzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Second Affiliated Hospital of Guangzhou Medical University7 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University5 Zhujiang Hospital5 Sun Yat-sen University5 Akeso3
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Guanzhou

54 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
An Open-label Study of SG1827 Combined With Anti-PD-1/PD-L1 Antibody and Bevacizumab in Patients With Advanced Solid Tumors
NCT07774611Advanced Solid Tumors
Hangzhou Sumgen Biotech Co., Ltd.
Phase 1/2
180
Chongqing, Fuzhou, Guanzhou, Chengde, Haerbin, Xinxiang, Changsha, Changchun
2026-09-22
Recruiting
Node-Sparing Short-Course Radiotherapy (25 Gy/5 Fractions) Combined With Chemoimmunotherapy as Neoadjuvant Treatment for Locally Advanced Esophageal Squamous Cell Carcinoma๏ผšA Prospective Single-Arm, Phase II Study
NCT07808853ESCC
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2
33
Guanzhou
2026-09-10
By invitation
Racecadotril for Organ Injury in Sepsis Patients
NCT07454421Sepsis
Zhujiang Hospital
Phase 1/2
44
Guanzhou
2026-05-06
Not yet open
Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis
NCT07451665Takayasu Arteritis (TAK)
Chinese SLE Treatment And Research Group
Phase 4
180
Beijing, Guanzhou, Shenzhen, Nanning, Jiaozuo, Luoyang, Wuhan, Nanjing
2026-04-01
Recruiting
A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
NCT07367529Advanced Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
465
Beijing, Chongqing, Guangzhou, Guanzhou, Zhongshan, Nanning, Cangzhou, Harbin
2026-02-26
By invitation
Endoscopic Nipple-Sparing Mastectomy (E-NSM) With Immediate Multistage Autologous Fat Grafting(IMAFG) for Total Breast Reconstruction Via the Axillary Incision
NCT07352137Breast Cancer, Breast Reconstruction
Guangdong Provincial Hospital of Traditional Chinese Medicine
Not applicable
20
Guanzhou
2026-01-13
Recruiting
ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
NCT07038096Small Cell Lung Cancer, Neuroendocrine Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2
350
Guanzhou
2025-09-23
Not yet open
Assessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23)
NCT07032532Peripheral T Cell Lymphoma
Sun Yat-sen University
Phase 2
35
Guanzhou
2025-07
Recruiting
AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer
NCT06951503Colorectal Adenocarcinoma
Akeso
Phase 3
560
Guanzhou
2025-05-27
Not yet open
To Evaluate the Tolerability and Pharmacokinetics of TQB2101 for Injection in Patients With Advanced Malignant Tumors
NCT06948539Breast Cancer, Lung Cancer, Colorectal Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
66
Guanzhou
2025-04
Recruiting
Proton Therapy for Recurrent Nasopharyngeal Carcinoma
NCT07412314Recurrent Nasopharyngeal Carcinoma
Guangzhou Concord Cancer Center
Not applicable
52
Guangzhou, Guanzhou
2025-03-10
Recruiting
Characteristics and Clinical Significance of Gut Microbiota in Patients With Monoclonal Gammopathy
NCT06690593Monoclonal Gammopathy of Undetermined Significance (MGUS), Intestinal Flora, Multiple Myeloma, M-Protein
Zhujiang Hospital
Observational
2,990
Guanzhou
2024-12-26
Recruiting
Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma
NCT06730308Thymoma
Sun Yat-sen University
Phase 2
45
Guanzhou
2024-11-20
Recruiting
Peripheral Scoring Drug-coated Balloon in the Treatment of Hemodialysis Arteriovenous Fistula Stenosis
NCT06422845Arteriovenous Fistula Stenosis
DK Medical Technology (Suzhou) Co., Ltd.
Not applicable
328
Hefei, Beijing, Chongqing, Guanzhou, Huizhou, Shenzhen, Liuzhou, Nanning
2024-09-30
Recruiting
RC48 in Combination With AK104 and Bevacizumab in OCCC
NCT06540729Ovary Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
39
Guanzhou
2024-09-24
Recruiting
Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Pain, Anxiety and Depression in Patients With Resectable Head and Neck Squamous Cell Carcinoma
NCT06575322Head and Neck Squamous Cell Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
302
Guanzhou
2024-09-01
Active, closed
Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
NCT06347003Severe Hypertriglyceridemia
Arrowhead Pharmaceuticals
Phase 3
446
Bengbu, Beijing, Guangzhou, Guanzhou, Liuzhou, Xingtai, Luoyang, Wuhan
2024-07-22
Recruiting
Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.
NCT06492408Hepatic Cancer, Surgery
Second Affiliated Hospital of Guangzhou Medical University
Phase 2
90
Guanzhou
2024-07-01
Recruiting
Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.
NCT06492421Lung Cancer, Surgery, Non-small Cell Lung Cancer
Second Affiliated Hospital of Guangzhou Medical University
Phase 2
90
Guanzhou
2024-07-01
Recruiting
Anti-cancer DC Cell Vaccination to Treat Solid Tumors
NCT06477614Solid Tumor, Adult, DC
Second Affiliated Hospital of Guangzhou Medical University
Phase 1
60
Guanzhou
2024-06-05
Not yet open
Compare the Accuracy of ctDNA-MRD and MVI Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma
NCT06449846Hepatocellular Carcinoma Resectable, Surgery, Recurrence
Zhujiang Hospital
Observational
152
Foshan, Guangzhou, Guanzhou
2024-06-01
Not yet open
Henagliflozin's Impact on Prediabetes Remission
NCT06448130PreDiabetes, Prediabetic State, Type 2 Diabetes, Glucose Metabolism Disorders
Shandong Provincial Hospital
Phase 4
984
Chuzhou, Hefei, Fuzhou, Lanzhou, Foshan, Guangzhou, Guanzhou, Shenzhen
2024-06
Recruiting
bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC
NCT06061276Liver Diseases, Hepatocellular Carcinoma, Immunotherapy, Camrelizumab
Sun Yat-sen University
Not applicable
40
Guanzhou
2024-05-20
Recruiting
A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors
NCT06431243Advanced Solid Tumor
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 1/2
132
Guanzhou, Chengdu
2024-05-08
Recruiting
Adding Of Naxitamb In Induction Therapy For High Risk Neuroblastoma
NCT06574698Neuroblastoma, GD2 Antibody (Naxitamab)
Guangzhou Women and Children's Medical Center
Observational
64
Guanzhou
2024-05-06
Recruiting
Intestinal Flora and Immunity in Monoclonal Gammopathy Patients
NCT06539832Multiple Myeloma, MGUS, Gut Microbiota, Infections
Zhujiang Hospital
Observational
300
Guanzhou
2024-05-01
Recruiting
A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia
NCT06387069Acute Myeloid Leukemia
Hutchmed
Phase 3
316
Hefei, Beijing, Chongqing, Fuzhou, Quanzhou, Xiamen, Guangzhou, Guanzhou
2024-04-26
Recruiting
Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases
NCT06265350Hepatocellular Carcinoma, Liver Cancer Stage IV, Pulmonary Metastases, Cadonilimab
Sun Yat-sen University
Not applicable
80
Guanzhou
2024-02-02
Recruiting
CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
NCT06560827HCC
CARsgen Therapeutics Co., Ltd.
Phase 1
30
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guanzhou, Hangzhou, Shanghai
2023-10-08
Recruiting
A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
NCT05934513Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Genfleet Therapeutics (Shanghai) Inc.
Phase 1/2
95
Guanzhou
2023-09-06
Recruiting
A Study of NBL-020 Injection in Subjects With Advanced Malignant Tumors.
NCT05877924Advanced Malignant Tumors
NovaRock Biotherapeutics, Ltd
Phase 1
200
Guanzhou
2023-08-15
Recruiting
Exploring Cancer Evolution, Prognostic and Predictive Biomarkers in EGFR-mutant NSCLC
NCT05997719Non-small Cell Lung Cancer
Sun Yat-sen University
Observational
150
Guanzhou
2023-08-10
Not yet open
A Multicenter Prospective Cohort Study Study of CLAG Regimen in Acute Myeloid Leukemia Patients With First-induction Failure
NCT05875649AML
Nanfang Hospital, Southern Medical University
Observational
137
Guanzhou
2023-07-02
Recruiting
Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC
NCT05800340Non-Small Cell Lung Cancer, RET Driver Mutation, BRAF V600 Mutation, Erb-B2 Receptor Tyrosine Kinase Exon 20 Mutation
Guangdong Provincial People's Hospital
Phase 2
30
Guanzhou
2023-04-04
Recruiting
Pre-warning Risk Scoring System for Sudden Cardiac Death
NCT06440083Sudden Cardiac Death
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
100,000
Guanzhou
2023-03-02
Active, closed
Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 + Serplulimab +Chemotherapy Versus Placebo + Serplulimab + Chemotherapy in First-Line Treatment of Patients With Recurrent or Metastatic NPC
NCT05513573Nasopharyngeal Carcinoma by AJCC V8 Stage
Shanghai Henlius Biotech
Phase 2
75
Guanzhou
2022-12-14
Active, closed
Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent ฮฒ-Thalassemia
NCT05577312Beta-Thalassemia
Bioray Laboratories
Phase 1/2
39
Guangzhou, Guanzhou, Shenzhen, Nanning, Changsha, Tianjin
2022-11-02
Recruiting
Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Head and Neck Squamous Cell Carcinoma (REDUCTION-I)
NCT05582265Head and Neck Squamous Cell Carcinomas
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
537
Guanzhou, Zhongshan, Shenzhen
2022-10-28
Recruiting
Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC
NCT05536505MRD
Guangdong Association of Clinical Trials
Phase 2
180
Beijing, Chongqing, Foshan, Fuzhou, Guangzhou, Guanzhou, Hangzhou, Hefei
2022-09-13
Active, closed
A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer
NCT05382442Metastatic Colorectal Cancer
Akeso
Phase 2
254
Guanzhou
2022-06-27
By invitation
A Follow-up Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B
NCT06707922Chronic Hepatitis B
Xiamen Amoytop Biotech Co., Ltd.
Not applicable
350
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Guanzhou, Harbin, Hefei
2022-03-18
Recruiting
Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse
NCT05270200Leukemia, Myeloid, Acute
Zhujiang Hospital
Phase 1/2
40
Guanzhou
2022-02-01
Recruiting
A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors
NCT05170958Advanced Solid Tumor
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
396
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Guanzhou, Nanning
2022-01-06
Active, closed
A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC
NCT04736823NSCLC
Akeso
Phase 2
265
Guanzhou
2021-02-01
Active, closed
Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma
NCT04718415Oral Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
51
Guangzhou, Guanzhou
2021-01-23
Active, closed
CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma
NCT04718883Mantle Cell Lymphoma
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 2
59
Beijing, Fuzhou, Guanzhou, Zhengzhou, Nanjing, Shanghai, Tianjin, Hangzhou
2021-01-13
Active, closed
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
NCT04280718Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
argenx
Phase 2
229
Beijing, Changsha, Chengdu, Chifeng, Fuzhou, Guangzhou, Guanzhou, Guiyang
2020-09-18
Active, closed
ASPIrin in Reducing Events in Dialysis ( ASPIRED )
NCT04381143CKD (Chronic Kidney Disease) Stage 5D
Guangdong Provincial People's Hospital
Phase 4
9,082
Fuzhou, Longyan, Lanzhou, Dongguan, Foshan, Guangzhou, Guanzhou, Heyuan
2020-07-30
Recruiting
Correlation of Microbiome and Metabonomics With IgA Nephropathy
NCT05190848IgA Nephropathy
Guangdong Provincial People's Hospital
Observational
600
Guangzhou, Guanzhou
2020-05-01
Active, closed
A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer
NCT04169997Ovarian Cancer
Impact Therapeutics, Inc.
Phase 3
404
Guanzhou, Shanghai
2019-12-24
Recruiting
Infusion of PD1/PDL1/CTLA4 Inhibitors Via Hepatic Arterial for Immunotherapy of Hepatocellular Carcinoma
NCT03949231Liver Cancer
Second Affiliated Hospital of Guangzhou Medical University
Phase 3
200
Guanzhou
2019-01-01
Recruiting
IT or IA Infusion of PD1/PDL1/CTLA4 Inhibitors Versus IV for Immunotherapy of Head/Neck Cancers (HNC)
NCT03952065Head/Neck Neoplasm
Second Affiliated Hospital of Guangzhou Medical University
Phase 2/3
200
Guanzhou
2019-01-01
Recruiting
TCR-T Cell Immunotherapy of Lung Cancer and Other Solid Tumors
NCT03778814Nonsmall Cell Lung Cancer, Solid Tumor, Adult
Second Affiliated Hospital of Guangzhou Medical University
Phase 1
30
Guanzhou
2018-12-01
Recruiting
Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
NCT03755739Hepatocarcinoma, Lung Cancer, Melanoma, Renal Cancer
Second Affiliated Hospital of Guangzhou Medical University
Phase 2/3
200
Guanzhou
2018-11-01
Rows per page Showing 1–54 of 54
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/guanzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 54 of those studies with a site in Guanzhou.

How many clinical trials are recruiting in Guanzhou?

34 of the 54 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 7 have not yet opened recruitment, 10 are active but closed to new participants, and 3 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Guanzhou), 54 studies
PhaseStudiesRecruitingShare
Phase 214725.9%
Observational9716.7%
Phase 1/29616.7%
Not applicable6411.1%
Phase 36411.1%
Phase 1549.3%
Phase 4305.6%
Phase 2/3223.7%

Most active sponsors

Lead sponsors with the most studies (Guanzhou)
Lead sponsorStudiesRecruiting
Second Affiliated Hospital of Guangzhou Medical University77
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University54
Sun Yat-sen University54
Zhujiang Hospital53
Akeso31
Guangdong Provincial People's Hospital32
argenx10
Arrowhead Pharmaceuticals10
Bioray Laboratories10
CARsgen Therapeutics Co., Ltd.11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.